Adding immunotherapy after initial treatment can benefit metastatic lung cancer patients
Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy—meaning all known sites of their cancer were either treated with ...
Jul 11, 2019
0
5